EA201991175A1 - Применение в медицине интерферона-лямбда для лечения фиброза - Google Patents

Применение в медицине интерферона-лямбда для лечения фиброза

Info

Publication number
EA201991175A1
EA201991175A1 EA201991175A EA201991175A EA201991175A1 EA 201991175 A1 EA201991175 A1 EA 201991175A1 EA 201991175 A EA201991175 A EA 201991175A EA 201991175 A EA201991175 A EA 201991175A EA 201991175 A1 EA201991175 A1 EA 201991175A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fibrosis
interferon
lambda
treatment
medicine
Prior art date
Application number
EA201991175A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201991175A1 publication Critical patent/EA201991175A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к способам лечения фиброза. В описании описано новое исследование, которое демонстрирует, что интерферон-лямбда обладает противофиброзными эффектами прямого действия как in vitro, так и in vivo и может использоваться для обеспечения эффективных новых способов терапии для лечения множества типов фиброза.
EA201991175A 2016-12-20 2017-12-20 Применение в медицине интерферона-лямбда для лечения фиброза EA201991175A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1621728.3A GB201621728D0 (en) 2016-12-20 2016-12-20 Methods
PCT/EP2017/083949 WO2018115199A1 (en) 2016-12-20 2017-12-20 Medical use of interferon-lambda for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
EA201991175A1 true EA201991175A1 (ru) 2019-11-29

Family

ID=58284677

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991175A EA201991175A1 (ru) 2016-12-20 2017-12-20 Применение в медицине интерферона-лямбда для лечения фиброза

Country Status (12)

Country Link
US (2) US20190374610A1 (ru)
EP (1) EP3558342A1 (ru)
JP (2) JP2020511415A (ru)
CN (1) CN110381985A (ru)
AR (1) AR110404A1 (ru)
BR (1) BR112019012084A2 (ru)
CA (1) CA3044949A1 (ru)
EA (1) EA201991175A1 (ru)
GB (1) GB201621728D0 (ru)
TW (1) TW201828973A (ru)
UY (1) UY37534A (ru)
WO (1) WO2018115199A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220275041A1 (en) * 2018-08-23 2022-09-01 Exalt Therapeutics, Llc Modified ifnl3 polypeptides comprising a pharmacokinetic enhancing moiety and their uses
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
CN110882381B (zh) * 2019-12-18 2020-11-17 中国人民解放军陆军军医大学第一附属医院 重组IFN-λ1蛋白在制备防治炎症性骨丢失药物中的应用
WO2021119749A1 (en) * 2019-12-20 2021-06-24 The Council Of The Queensland Institute Of Medical Research Treatment of gastrointestinal disease
CN114736878B (zh) * 2021-01-07 2024-04-19 秦皇岛摩登狗生物科技有限公司 共表达猪干扰素l3和猪白介素22重组杆状病毒及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
WO2002081507A2 (en) 2001-04-06 2002-10-17 Maxygen Holdings Ltd. Interferon gamma polypeptide variants
US20060110358A1 (en) 2002-08-28 2006-05-25 Hsu Henry H Combination therapy for treatment of fibrotic disorders
AU2003299962A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004105684A2 (en) 2003-05-16 2004-12-09 Intermune, Inc. Combination therapy for proliferative disorders
SI1644412T2 (sl) 2003-07-01 2018-11-30 Ucb Biopharma Sprl Modificirani fab fragmenti protiteles
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20070258946A1 (en) * 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
WO2005110478A2 (en) 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2009529027A (ja) 2006-03-08 2009-08-13 ビオメトード ヒトインターフェロンガンマ（ＩＦＮγ）変異体
CN101842387B (zh) 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
WO2009149377A1 (en) * 2008-06-05 2009-12-10 Zymogenetics, Llc Use of pegylated type iii interferons for the treatment of hepatitis c
WO2010045261A1 (en) 2008-10-13 2010-04-22 Zymogenetics, Llc Single chain fc type iii interferons and methods of using same
WO2010048468A1 (en) 2008-10-23 2010-04-29 Concert Pharmaceuticals, Inc. Deuterated macrocyclic inhibitors of viral ns3 protease
EP2350124A1 (en) * 2008-11-20 2011-08-03 Zymogenetics, Inc. Il-29 mutants and uses thereof
WO2011075605A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated interferon variants and methods of use
IT1400236B1 (it) 2010-05-10 2013-05-24 Univ Bari Impiego di composti noti per il trattamento dell'insufficienza renale cronica(irc)
CN102584979B (zh) * 2011-01-18 2015-10-14 北京凯因科技股份有限公司 PEG化干扰素λ
CA2869899C (en) 2012-03-28 2021-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel interferon-.lambda.4 (ifnl4) protein, related nucleic acid molecules, and uses thereof
DK3416675T3 (da) * 2016-02-19 2021-06-14 Eiger Biopharmaceuticals Inc Behandling af hepatitis-delta-virusinfektion med interferon lambda

Also Published As

Publication number Publication date
WO2018115199A1 (en) 2018-06-28
BR112019012084A2 (pt) 2019-11-12
US20240000893A1 (en) 2024-01-04
JP2020511415A (ja) 2020-04-16
UY37534A (es) 2018-09-28
US20190374610A1 (en) 2019-12-12
CA3044949A1 (en) 2018-06-28
GB201621728D0 (en) 2017-02-01
AR110404A1 (es) 2019-03-27
EP3558342A1 (en) 2019-10-30
CN110381985A (zh) 2019-10-25
US11975046B2 (en) 2024-05-07
TW201828973A (zh) 2018-08-16
JP2022081677A (ja) 2022-05-31

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
EA201691582A1 (ru) Новые фармацевтические препараты
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
EA201790398A1 (ru) Способы лечения заболевания печени
EA201790737A1 (ru) Комбинированная терапия
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201692109A1 (ru) Варианты антител к фактору d и их применение
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
CL2015002897A1 (es) Inhibidores de bace1
PH12018501443A1 (en) Methods of administering hepcidin
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EA201791933A1 (ru) Ингибирование активности olig2
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине